Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma

被引：0
|
作者：
Weller, Michael
Papachristodoulou, Alexandros
Hentschel, Bettina
Gramatzki, Dorothee
Felsberg, Joerg
Loeffler, Markus
Schackert, Gabriele
Westphal, Manfred
Tonn, Joerg
Silginer, Manuela
von Deimling, Andreas
Pietsch, Torsten
Reifenberger, Guido
Roth, Patrick
机构：
[1] Univ Hosp Zurich, Dept Neurol, Zurich, Switzerland
[2] Univ Leipzig, Inst Med Informat Stat & Epidemol, Leipzig, Germany
[3] Heinrich Heine Univ Hosp, Dept Neuropathol, Dusseldorf, Germany
[4] Univ Hosp Dresden, Dept Neurosurg, Dresden, Germany
[5] Univ Hamburg, Dept Neurosurg, Hamburg, Germany
[6] Univ Munich LMU, Dept Neurosurg, Munich, Germany
[7] Heidelberg Univ, Dept Neuropathol, Heidelberg, Germany
[8] Univ Bonn, Dept Neuropathol, Bonn, Germany
[9] Univ Hosp Zurich, Zurich, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2013
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy
    Nguyen, HuyTram N.
    Lie, Amy
    Li, Tie
    Chowdhury, Reshmi
    Liu, Fei
    Ozer, Byram
    Wei, Bowen
    Green, Richard M.
    Ellingson, Benjamin M.
    Wang, He-jing
    Elashoff, Robert
    Liau, Linda M.
    Yong, William H.
    Nghiemphu, Phioanh L.
    Cloughesy, Timothy
    Lai, Albert
    NEURO-ONCOLOGY, 2017, 19 (03) : 394 - 404
  • [22] Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis
    Alnahhas, Iyad
    Alsawas, Mouaz
    Rayi, Appaji
    Palmer, Joshua D.
    Raval, Raju
    Ong, Shirley
    Giglio, Pierre
    Murad, Mohammad Hassan
    Puduvalli, Vinay
    NEURO-ONCOLOGY ADVANCES, 2020, 2 (01)
  • [23] Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
    Lim, Michael
    Weller, Michael
    Idbaih, Ahmed
    Steinbach, Joachim
    Finocchiaro, Gaetano
    Raval, Raju R.
    Ansstas, George
    Baehring, Joachim
    Taylor, Jennie W.
    Honnorat, Jerome
    Petrecca, Kevin
    De Vos, Filip
    Wick, Antje
    Sumrall, Ashley
    Sahebjam, Solmaz
    Mellinghoff, Ingo K.
    Kinoshita, Masashi
    Roberts, Mustimbo
    Slepetis, Ruta
    Warad, Deepti
    Leung, David
    Lee, Michelle
    Reardon, David A.
    Omuro, Antonio
    NEURO-ONCOLOGY, 2022, 24 (11) : 1935 - 1949
  • [24] Mutation Analysis of the TERT Promoter in Hepatoblastoma and Glioblastoma by Sanger Sequencing and Pyrosequencing Assays
    Sarabia, S. F.
    Mehta, V. P.
    Tran, M. T.
    Fisher, K. E.
    Adesina, A. M.
    Finegold, M. J.
    Lopez-Terrada, D. H.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (06): : 827 - 828
  • [25] REVERSAL OF GLIOBLASTOMA REPLICATIVE IMMORTALITY IN A TERT PROMOTER MUTATION-DEPENDENT MANNER
    Mancini, Andrew
    Xavier-Magalhaes, Ana
    Woods, Wendy
    Nguyen, Kien-Thiet
    Amen, Alexandra
    McKinney, Andrew
    Hayes, Josie
    Song, Jun
    Costa, Bruno
    Perez-Pinera, Pablo
    Costello, Joseph
    NEURO-ONCOLOGY, 2017, 19 : 57 - 58
  • [26] New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma
    Pierini, Tiziana
    Nardelli, Carlotta
    Fernandez, Anair Graciela Lema
    Pierini, Valentina
    Pellanera, Fabrizia
    Nofrini, Valeria
    Gorello, Paolo
    Moretti, Martina
    Arniani, Silvia
    Roti, Giovanni
    Giovenali, Paolo
    Lupattelli, Marco
    Metro, Giulio
    Molica, Carmen
    Castrioto, Corrado
    Corinaldesi, Rodolfo
    Laurenti, Maria Elena
    Ascani, Stefano
    Mecucci, Cristina
    La Starza, Roberta
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2020, 8 (01)
  • [27] New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma
    Tiziana Pierini
    Carlotta Nardelli
    Anair Graciela Lema Fernandez
    Valentina Pierini
    Fabrizia Pellanera
    Valeria Nofrini
    Paolo Gorello
    Martina Moretti
    Silvia Arniani
    Giovanni Roti
    Paolo Giovenali
    Marco Lupattelli
    Giulio Metro
    Carmen Molica
    Corrado Castrioto
    Rodolfo Corinaldesi
    Maria Elena Laurenti
    Stefano Ascani
    Cristina Mecucci
    Roberta La Starza
    Acta Neuropathologica Communications, 8
  • [28] The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival
    Shu, Chang
    Wang, Qiong
    Yan, Xiaoling
    Wang, Jinhuan
    CANCER MEDICINE, 2018, 7 (08): : 3704 - 3712
  • [29] Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients
    Giunco, S.
    Padovan, M.
    Angelini, C.
    Cavallin, F.
    Cerretti, G.
    Morello, M.
    Caccese, M.
    Rizzo, B.
    d'Avella, D.
    Puppa, A. D.
    Chioffi, F.
    De Bonis, P.
    Zagonel, V.
    De Rossi, A.
    Lombardi, G.
    ESMO OPEN, 2023, 8 (03)
  • [30] TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma
    Kikuchi, Zensho
    Shibahara, Ichiyo
    Yamaki, Tetsu
    Yoshioka, Ema
    Shofuda, Tomoko
    Ohe, Rintaro
    Matsuda, Ken-ichiro
    Saito, Ryuta
    Kanamori, Masayuki
    Kanemura, Yonehiro
    Kumabe, Toshihiro
    Tominaga, Teiji
    Sonoda, Yukihiko
    NEURO-ONCOLOGY ADVANCES, 2020, 2 (01)
12345